当前位置: 首页 > 期刊 > 《中国医药科学》 > 2022年第9期
编号:113373
结肠癌治疗研究进展
http://www.100md.com 2022年7月13日 中国医药科学 2022年第9期
靶向治疗,免疫治疗
     薛思麒 何晶 唐勇

    [摘要]结肠癌是最常见的癌症相关死亡原因,在不同的癌症相关死亡中仅次于肺癌。结肠癌的治疗取决于多种因素,包括结肠癌的性质(散发性或遗传性)、分子因素、年龄、结肠癌分期等。目前的治疗方法有手术/息肉切除、化疗、放疗、联合治疗、免疫治疗等;先进的治疗方法有基因治疗、细胞治疗、靶向免疫治疗等,目前还处于研发阶段。然而,每种治疗方案都有副作用,而且每种疗法都有缺点,如肿瘤复发、靶点缺乏特异性以及抗癌药物的耐药性等。因此,对结肠癌治疗方法的研究值得探索。虽然结肠癌治疗已经达到了较高的水平,但更多的学者和研究者及临床医生仍在继续为研发更好的结肠癌治疗方法而努力。

    [关键词]结肠癌;化疗;靶向治疗;免疫治疗

    [中图分类号] R735.3+5? [文献标识码] A? [文章编号]2095-0616(2022)09-0058-04

    Research advances in the treatment of colon cancer

    XUE? Siqi? HE? Jing? TANG? Yong

    Department of Gastroenterology, Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang, Urumqi 830000,China

    [Abstract] Colon cancer is the most common cause of death from cancer, which is second only to lung cancer. The treatment of colon cancer depends on multifarious factors, including the nature (sporadic or hereditary), molecular factors, age, stage of colon cancer, etc. Current treatment includes surgery/polypectomy, chemotherapy, radiotherapy, combined therapy, and immunotherapy. The advanced treatment methods consist of gene therapy, cell therapy, and targeted immunotherapy, which are still under research and development. Nevertheless ......

您现在查看是摘要页,全文长 15141 字符